Humacyte (NASDAQ:HUMA) Price Target Cut to $3.00 by Analysts at BTIG Research

Humacyte (NASDAQ:HUMA) had its price target decreased by BTIG Research from $6.00 to $3.00 in a research report released on Friday,Benzinga reports. BTIG Research currently has a buy rating on the stock.

A number of other equities analysts have also recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Humacyte in a report on Monday, December 1st. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of Humacyte in a report on Tuesday, March 17th. UBS Group restated a “buy” rating on shares of Humacyte in a research report on Monday, December 1st. Benchmark decreased their price objective on Humacyte from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, January 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Humacyte in a research report on Monday, December 29th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.71.

Humacyte Stock Down 13.2%

Shares of HUMA stock opened at $0.68 on Friday. Humacyte has a 12 month low of $0.67 and a 12 month high of $2.93. The stock has a market cap of $126.52 million, a P/E ratio of -2.94 and a beta of 1.89. The company has a current ratio of 1.62, a quick ratio of 0.90 and a debt-to-equity ratio of 2.97. The company has a 50 day simple moving average of $1.04 and a two-hundred day simple moving average of $1.28.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Friday, March 27th. The company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). The business had revenue of $0.47 million during the quarter, compared to the consensus estimate of $1.35 million. On average, research analysts expect that Humacyte will post -1.27 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. United Asset Strategies Inc. raised its holdings in Humacyte by 13.5% during the fourth quarter. United Asset Strategies Inc. now owns 209,608 shares of the company’s stock valued at $201,000 after acquiring an additional 25,000 shares during the period. SG Americas Securities LLC lifted its position in shares of Humacyte by 50.3% in the fourth quarter. SG Americas Securities LLC now owns 34,075 shares of the company’s stock valued at $33,000 after acquiring an additional 11,411 shares in the last quarter. Integrated Advisors Network LLC bought a new position in shares of Humacyte in the third quarter worth about $151,000. Independent Advisor Alliance grew its position in shares of Humacyte by 49.4% during the third quarter. Independent Advisor Alliance now owns 36,240 shares of the company’s stock worth $63,000 after purchasing an additional 11,991 shares in the last quarter. Finally, Truist Financial Corp purchased a new stake in shares of Humacyte during the third quarter worth about $28,000. Institutional investors own 44.71% of the company’s stock.

Key Stories Impacting Humacyte

Here are the key news stories impacting Humacyte this week:

• Positive Sentiment: D. Boral Capital reaffirmed a “buy” rating and set an outsized $25.00 price target, signaling strong upside expectations from that firm. Benzinga
• Positive Sentiment: Humacyte named Rick McElheny SVP of Business Development to expand collaborations and commercialization efforts—management hire aimed at accelerating partnerships that could drive future revenue. GlobeNewswire: Appointment
• Neutral Sentiment: Full earnings call transcript is available for investors wanting management commentary and Q&A that could clarify outlook and commercial plans. Earnings Call Transcript
• Negative Sentiment: Q4 results: GAAP loss of ($0.13) per share met consensus, but revenue came in at roughly $0.47–0.5M versus analyst expectations near $1.35M (and full‑year sales only $2.0M). The revenue shortfall and low near-term sales reduce near-term visibility and likely pressured the stock. MarketBeat: Earnings Press Release Zacks
• Negative Sentiment: BTIG reduced its price target from $6.00 to $3.00 (still a “buy”), signaling a more cautious near-term outlook from another sell-side firm and lowering consensus upside. Benzinga

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.